{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03254758",
      "OrgStudyIdInfo": {
        "OrgStudyId": "ADR-001-01"
      },
      "Organization": {
        "OrgFullName": "Rohto Pharmaceutical Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "A Study of ADR-001 in Patients With Liver Cirrhosis",
      "OfficialTitle": "A Phase 1/2 Study of ADR-001 in Patients With Liver Cirrhosis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 20, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "August 3, 2017",
      "StudyFirstSubmitQCDate": "August 16, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 18, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "September 9, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 16, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Rohto Pharmaceutical Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a first-in-human Phase1/2 study of ADR-001, adipose-derived mesenchymal stem cells (AD-MSCs). The safety and preliminary efficacy are evaluated in Phase 1 in patients with liver cirrhosis caused by Hepatitis C or Nonalcoholic Steatohepatitis and a recommended Phase 2 dose is determined by the evaluation. The exploratory efficacy and safety are investigated against the same target population in Phase 2.",
      "DetailedDescription": "Patients with decompensated liver cirrhosis (Child-Pugh score; Grade B) caused by Hepatitis C or Nonalcoholic Steatohepatitis are enrolled to the study. In Phase 1, one of 3 doses of AD-MSCs is administered by 1 hour single intravenous infusion. Patients are hospitalized for 1 week and a recommended dose for Phase 2 is determined by the evaluation of the safety and efficacy. In Phase 2, patients with the same disease criteria are enrolled and dosed to investigate the exploratory efficacy and safety.\n\nThe safety and efficacy are evaluated until 24 weeks after dosing both in Phase 1 and Phase 2."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Decompensated Liver Cirrhosis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "27",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal stem cell",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Phase 1 Dose escalation : low Mid High Single administalation of ADR-001\n\nPhase 2 The recommended dose of ADR-001",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal stem cell"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal stem cell",
            "InterventionDescription": "Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.\n\nPhase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal stem cell"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety profile of ADR-001 including the incidence of adverse events (Phase 1)",
            "PrimaryOutcomeDescription": "Safety will be evaluated based on the medical review of adverse event reports and the results of clinical laboratory tests, vital sign, and physical examinations.",
            "PrimaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "PrimaryOutcomeMeasure": "Improvement rate of Child-Pugh score (Phase 2)",
            "PrimaryOutcomeDescription": "Improvement rate of Child-Pugh score from the baseline will be evaluated.",
            "PrimaryOutcomeTimeFrame": "24 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change of liver function evaluated by Child-Pugh score (Phase 1)",
            "SecondaryOutcomeDescription": "Change of liver function from the baseline will be evaluated by Child-Pugh score.",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Improvement rate of Child-Pugh score (Phase 1)",
            "SecondaryOutcomeDescription": "Improvement rate of Child-Pugh score from the baseline will be evaluated.",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Improvement rate of Child-Pugh grade (Phase 1)",
            "SecondaryOutcomeDescription": "Improvement rate of Child-Pugh grade from the baseline will be evaluated.",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change of liver function evaluated by Child-Pugh score (Phase 2)",
            "SecondaryOutcomeDescription": "Change of liver function from the baseline will be evaluated by Child-Pugh score.",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Improvement rate of Child-Pugh grade (Phase 2)",
            "SecondaryOutcomeDescription": "Improvement rate of Child-Pugh grade from the baseline will be evaluated.",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Safety profile of ADR-001 including the incidence of adverse events (Phase 2)",
            "SecondaryOutcomeDescription": "Safety will be evaluated based on the medical review of adverse event reports and the results of clinical laboratory tests, vital sign, and physical examinations.",
            "SecondaryOutcomeTimeFrame": "24 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMen and women ≥ 20 years of age\nChronic hepatitis C or nonalcoholic steatohepatitis(NASH)\nChild-Pugh grade B liver cirrhosis\nECOG Performance Status ≤ 2\n\nExclusion Criteria:\n\nLiver cirrhosis patients other than hepatitis C or NASH\nMalignant neoplasm (except hepatocellular carcinoma patients without recurrence more than 2 years)\nHistory of venous thrombosis or pulmonary embolism\nSerum creatinine ≥ 2 mg/dL or T-Bil ≥ 5.0 mg/dL\nInfection with hepatitis B, HIV, ATLV-1 or parvovirus B19\nPatients experienced transplantation or cell therapy\nPregnancy or positive on pregnancy test\nComplications of significant heart disease, kidney disorder, or respiratory disease\nDrug or alcohol abuse",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "20 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Rohto Pharmaceutical Co., Ltd.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+81-3-6823-6014",
            "CentralContactEMail": "adr-001@rohto.co.jp"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Shuji Terai, MD",
            "OverallOfficialAffiliation": "Niigata University Medical & Dental Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Niigata University Medical & Dental Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Niigata",
            "LocationZip": "951-8510",
            "LocationCountry": "Japan",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Division of Gastroenterology and Hepatology",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          },
          {
            "LocationFacility": "Nihon University Itabashi Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Tokyo",
            "LocationZip": "173-8610",
            "LocationCountry": "Japan",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Division of Gastroenterology and Hepatology",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008103",
            "ConditionMeshTerm": "Liver Cirrhosis"
          },
          {
            "ConditionMeshId": "D000005355",
            "ConditionMeshTerm": "Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10255",
            "ConditionBrowseLeafName": "Liver Cirrhosis",
            "ConditionBrowseLeafAsFound": "Liver Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafAsFound": "Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10262",
            "InterventionBrowseLeafName": "Liver Extracts",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}